Add BrightSurf on Google Email

Prenatal exposure to depression linked to neurodevelopmental disorders

A new study found that children of mothers with depression have a higher risk of neurodevelopmental disorders, regardless of antidepressant exposure. The study followed over 167,000 children and found a significant association between maternal depression and special educational needs in children.

SourcePLOS·JournalPLOS Medicine·TypeObservational study·DateSep 29, 2026

Older Americans are taking more medications, with 1 in 5 at risk for a major drug interaction

A recent USC-led study reveals that over 1 in 5 older adults are at risk for major drug interactions, despite a decline in their prevalence. Polypharmacy and dietary supplement polypharmacy have increased, with antidepressants, statins, and antiplatelet therapies being the most commonly used medications involved in these regimens.

SourceUniversity of Southern California·JournalJAMA·TypeObservational study·DateSep 24, 2026

Fish may be highly sensitive to antidepressants found in water

Researchers found that fish serotonin transporters, similar to human counterparts, can be highly sensitive to antidepressants found in water, highlighting potential risks to aquatic life. The study suggests prioritizing specific pharmaceuticals in environmental monitoring programs and deriving species-specific risk thresholds.

SourceTokyo University of Science·JournalEnvironmental Science & Technology·TypeExperimental study·DateSep 9, 2026

Widespread women's disease takes a mental toll – before and after diagnosis

A large Danish study reveals that women with endometriosis use more anxiety and depression medication before and after diagnosis, with differences persisting even after diagnosis. The study suggests that prolonged pain, uncertainty, and fertility problems may contribute to the mental strain, but an earlier diagnosis may not alleviate it.

SourceAarhus University·JournalHuman Reproduction·TypeData/statistical analysis·DateAug 19, 2026

Prozac appears to blunt formation of PTSD symptoms after traumatic injury in small study

A preliminary study found that people taking Prozac after a traumatic injury reported fewer PTSD symptoms and lower pain levels in the year following their injury. The study suggests that preventative medical interventions could reduce the formation of post-traumatic stress disorder symptoms.

SourceUniversity of Florida·JournalJournal of Orthopaedic Trauma·TypeRandomized controlled/clinical trial·DateAug 3, 2026

After anesthesia

Researchers found that female mice's microglia form prolonged contacts with neurons during recovery, leading to synaptic remodeling and plasticity. This phenomenon was not observed in male mice, highlighting differences in brain recovery processes between sexes.

SourceInstitute of Science and Technology Austria·JournalScience Advances·TypeExperimental study·DateJul 31, 2026

Time for a re-think of long-term antidepressant use

A new summary of evidence reveals that antidepressants have limited benefits beyond 12 months and may cause severe withdrawal symptoms. Researchers are calling for treatment reviews every six months and recommending gradual weaning strategies when discontinuing medication.

SourceAdelaide University·JournalAustralian Journal of General Practice·TypeSystematic review·DateJun 3, 2026

The Lancet Psychiatry: No clear link between common antidepressant use in pregnancy and autism or ADHD in children, finds most comprehensive study to date

A systematic review and meta-analysis published in The Lancet Psychiatry found no clear link between common antidepressant use in pregnancy and increased risk of neurodevelopmental disorders like autism and ADHD in children. However, the study suggests that genetic predisposition and other factors may contribute to an increased risk.

SourceThe Lancet·JournalThe Lancet Psychiatry·TypeMeta-analysis·DateMay 14, 2026

Opioids and other drugs accumulating in freshwater fish

A new study reveals that freshwater fish are accumulating antidepressants, opioids, and other drugs of abuse in their bodies, which can alter their behavior, development, and reproduction. The research uses a novel analytical method to detect these substances in small fish living in rivers receiving urban wastewater.

SourceUniversity of Waterloo·JournalEnvironmental Pollution·TypeExperimental study·DateApr 16, 2026

Mirtazapine for methamphetamine use disorder

In this randomized clinical trial, mirtazapine effectively reduced methamphetamine use in adults with methamphetamine use disorder. The study's findings have important implications for the treatment of this condition, which currently lacks approved pharmacotherapies.

SourceJAMA Network·JournalJAMA Psychiatry·DateApr 1, 2026

New PET imaging study reveals how ketamine relieves treatment-resistant depression

A new PET imaging study reveals that ketamine relieves treatment-resistant depression by altering AMPAR in brain regions, providing potential biomarker for personalized treatment. The study found that ketamine increased AMPAR density in several cortical regions and decreased it in reward-related areas, strongly correlating with reducti...

SourceYCU Advanced Medical Research Center·JournalMolecular Psychiatry·TypeImaging analysis·DateMar 6, 2026

“What causes the delay in antidepressant effects? ” DGIST identifies brain neuropeptides as key drivers behind delayed antidepressant effects for the first time

Researchers have identified brain neuropeptides as key drivers behind delayed antidepressant effects for the first time. The study found that medication-driven serotonin levels primarily serve as a 'starting signal' while the peptide plays a central role in brain recovery.

Study: Discontinuing antidepressants in pregnancy nearly doubles risk of mental health emergencies

Patients who stopped taking antidepressant medication during pregnancy had a nearly two-fold higher risk of experiencing mental health emergencies, with peaks in the first and ninth months. Researchers found no difference in prior mental health visits between those who continued or discontinued therapy.

SourceSociety for Maternal-Fetal Medicine·JournalPregnancy·TypeObservational study·DateFeb 11, 2026

One in four older Americans with dementia prescribed risky brain-altering drugs despite safety warnings

Research finds that nearly one in four Medicare beneficiaries with dementia are prescribed potentially harmful medications linked to falls, confusion, and hospitalization. Despite declines in prescribing rates, high levels of inappropriate prescribing persist among older adults with cognitive impairment.

SourceUniversity of California - Los Angeles Health Sciences·JournalJAMA·TypeData/statistical analysis·DateJan 12, 2026

Research spotlight: A subset of patients with depression could benefit from anti-inflammatory treatment

A subset of depressed individuals with chronic, low-grade inflammation may benefit from anti-inflammatory treatment, according to a systematic review and meta-analysis. The study found that anti-inflammatory medications significantly reduced depressive symptom severity and anhedonia in these patients.

SourceBrigham and Women's Hospital·JournalAmerican Journal of Psychiatry·TypeSystematic review·DateDec 10, 2025

The Lancet Psychiatry: Slow tapering plus therapy most effective strategy for stopping antidepressants, finds major meta-analysis

A systematic review and network meta-analysis of 76 randomised controlled trials found that slow tapering of antidepressants combined with psychological support prevented relapse over the following year to a similar extent as remaining on an antidepressant. This approach could change how coming off antidepressants is managed globally.

SourceThe Lancet·JournalThe Lancet Psychiatry·TypeMeta-analysis·DateDec 10, 2025

Long-term antidepressant use surges in Australia, sparking warnings of overprescribing

A new study found that long-term antidepressant use has increased by nearly 20% among young people aged 10-24, raising concerns about potential overprescribing. The study also found no meaningful improvement in efforts to wean patients off antidepressants, highlighting the need for a stronger framework for safely tapering medications.

SourceUniversity of South Australia·JournalPharmacoepidemiology and Drug Safety·TypeData/statistical analysis·DateDec 2, 2025

Adenosine is the metabolic common pathway of rapid antidepressant action: The coffee paradox

A recent landmark study identifies adenosine as the critical mediator of rapid antidepressant action, connecting ketamine, ECT, and hypoxia. The discovery raises questions about the potential interference of caffeine with these treatments, highlighting the need for further research on adenosinergic modulation in depression.

SourceGenomic Press·JournalBrain Medicine·TypeLiterature review·DateNov 11, 2025

New molecule reduces ethanol intake and drinking motivation in mice, with sex-dependent differences

A new compound MCH11, a monoacylglycerol lipase inhibitor, shows promising effects in reducing alcohol consumption and motivation to drink in mice. The molecule exhibits anxiolytic and antidepressant properties with sex-dependent efficacy, correcting genetic alterations associated with alcohol use disorder.

SourceUniversidad Miguel Hernandez de Elche·JournalBiomedicine & Pharmacotherapy·TypeExperimental study·DateNov 11, 2025

Antidepressants improve core depressive symptoms early on

A new analysis of the PANDA trial found that sertraline contributes to improvements in low mood and suicidal thinking within two weeks of taking the drug. The study also revealed an improvement in emotional symptoms of depression within two weeks, with continued benefits from six weeks to 12 weeks.

SourceUniversity College London·JournalNature Mental Health·TypeRandomized controlled/clinical trial·DateOct 30, 2025

Yueju Pill or escitalopram in MDD?

A randomized, double-blind trial compared Yueju Pill and escitalopram in treating major depressive disorder (MDD). The study found that Yueju Pill improved depression symptoms and increased serum brain-derived neurotrophic factor (BDNF) levels. Brain network patterns were also predictive of treatment response in the Yueju Pill group.

SourceShanghai Jiao Tong University Journal Center·JournalGeneral Psychiatry·TypeExperimental study·DateOct 24, 2025

Treatment timing is critical to Prozac's impact on mood behaviors

Researchers found that Prozac's impact on mood behaviors is critical to the timing of its administration, with early postnatal exposure leading to increased anxiety- and depression-like behaviors, while adolescent exposure had the opposite effect. This study provides crucial mechanistic insights into alterations in neurocircuits that r...

SourceElsevier·JournalBiological Psychiatry·TypeExperimental study·DateJul 7, 2025

Antidepressant use in teens contributes to increased pain sensitivity in adulthood

A new study from the University of Texas at El Paso finds that adolescent antidepressant use, particularly Prozac, may contribute to increased pain sensitivity in adulthood. The research suggests that early exposure to these medications can disrupt brain development and increase inflammatory markers, leading to heightened pain perception.

SourceUniversity of Texas at El Paso·JournalJournal of Psychiatric Research·DateMay 27, 2025

Common antidepressants could help the immune system fight cancer, UCLA study finds

A UCLA study found that selective serotonin reuptake inhibitors (SSRIs) can significantly enhance the ability of T cells to fight cancer and suppress tumor growth across various cancer types in mouse and human tumor models. SSRIs increased access to serotonin signals, making killer T cells happier and more effective at killing cancer c...

Nearly half of depression diagnoses could be considered treatment-resistant

A new study suggests that nearly half of depression diagnoses could be considered treatment-resistant, with 48% of patients trying at least two antidepressants and 37% trying four or more. This highlights the need for better treatment options to support patients who don't respond to first-line medications.

SourceUniversity of Birmingham·JournalThe British Journal of Psychiatry·TypeData/statistical analysis·DateMar 21, 2025

Antidepressants linked to faster cognitive decline in dementia

A new observational study suggests that antidepressants can accelerate cognitive decline in people with dementia, while certain medications appear to be less harmful. Researchers analyzed data from 18,740 patients and found that selective serotonin reuptake inhibitors (SSRIs) were associated with the fastest cognitive decline.

SourceKarolinska Institutet·JournalBMC Medicine·TypeObservational study·DateFeb 24, 2025

The role of ketamine in treatment-resistant depression

Ketamine has been shown to rapidly reduce depressive symptoms in patients with treatment-resistant depression, often within hours of administration. However, the long-term efficacy and safety of ketamine therapy remain uncertain, with potential risks including cognitive impairment and cardiovascular effects.

SourceXia & He Publishing Inc.·JournalJournal of Exploratory Research in Pharmacology·DateFeb 19, 2025